XML 50 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaboration Agreement - Schedule of Collaboration Revenue Related to U.S. XTANDI Net Sales (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration revenue related to U.S. XTANDI net sales $ 165,129 $ 149,220 $ 318,922 $ 261,230
U.S. [Member] | XTANDI [Member] | Collaborative agreement [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Collaboration revenue related to U.S. XTANDI net sales 165,129 149,220 318,922 261,230
U.S. [Member] | XTANDI [Member] | Collaborative agreement [Member] | Astellas Pharma Inc. [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
U.S. XTANDI net sales (as reported by Astellas) 330,257 298,440 637,843 522,460
Shared U.S. development and commercialization costs (95,055) (84,947) (225,639) (195,260)
Pre-tax U.S. profit 235,202 213,493 412,204 327,200
U.S. [Member] | XTANDI [Member] | Collaborative agreement [Member] | Medivation [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Medivation's share of pre-tax U.S. profit 117,601 106,747 206,102 163,600
Reimbursement of Medivation's share of shared U.S. costs $ 47,528 $ 42,473 $ 112,820 $ 97,630